Lilly Alzheimer drug fails to hit trial goals

Share this article:

Eli Lilly announced Friday that the Phase III trial for its its experimental Alzheimer's drug Solanezumab was a bust—tests showed that the drug failed to meet either of the Phase III targets among patients with mild to moderate Alzheimer's disease.

But Lilly added in a statement that Solanezumab is not finished yet. The reason for holding on: even though the Expedition trials didn't come through on both cognitive and function targets, the company said that if it pools the data from both trials and measures the cognitive impact alone, the drug did slow decline among patients with mild symptoms.

Jefferies analyst Jeffrey Holford was not impressed. He noted in his Friday research note that the cognitive impact was largely limited to the mild-Alzheimer's set, as opposed to significantly helping both mild and moderately affected patients. Holford also took issue with pooling the data for a good result. “With even mild patients not showing a significant benefit on cognition in Expediton 2 as a standalone study," he noted, "the magnitude and reliability of the benefit must be questioned at this point.”

Lilly said in a statement it will determine the next steps for the drug after meeting with regulators.

This was yet another blow to the Lilly pipeline. The company announced it July that its investigational schizophrenia drug mGLu2/3 also failed to hit its marks in clinical trials.

Analysts have viewed the Alzheimer's category with a high degree of skepticism, noting last month that even drugmakers set low expectations for their drugs.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...